Cancer Cell Line Based Drug to Control Pancreatic Cancer with Concomitant KRAS Mutation (original) (raw)

KRAS gene is a recurrently mutated gene pair in various cancers, including pancreatic adenocarcinoma. We aim to depict the omics landscape of a KRAS mutation and find potential novel drugs for pancreatic cancer patients with KRAS mutations. This study considers the cancer genome atlas and cancer cell line encyclopedia information for the KRAS mutation analysis in a multi-omics manner. We found that the genomics and transcriptomics patterns of a KRAS mutation are significantly different compared to the corresponding non-mutated pancreatic adenocarcinoma. Pancreatic cancer's prognosis is directly associated with a specific KRAS mutation and its protein's structure instability. Our analysis confirmed that Irinotecan could be a potential drug for pancreatic adenocarcinoma patients with KRAS G12D mutation.